CVS bought Aetna for $78B to fuse pharmacy, insurance and clinics into one front door

CVS Health was a retail pharmacy and pharmacy-benefit manager watching a fragmenting healthcare market and Amazon's 2017 interest in the drug business. In December 2017 it agreed to buy health insurer Aetna for $78 billion including debt, a vertical combination rather than a rival buying a rival.

The deal closed Nov. 28, 2018, after 28 state approvals, a Department of Justice clearance conditional on Aetna divesting its standalone Medicare Part D business, and contentious hearings in New York and California where regulators extracted premium-protection pledges and hundreds of millions in community-health commitments before signing off.

Aetna kept operating as a standalone business under the CVS Health umbrella, with Aetna CEO Mark Bertolini and two other Aetna representatives added to the CVS board and Aetna's controller becoming the combined company's CFO. CEO Larry Merlo stayed at the helm of what he called the industry's new 'front door to quality health care.'

A combined entity with $245B+ annual revenue, 9,700 stores, 1,100 clinics, 90M PBM members, and a targeted $750M in year-two cost savings.

CVS wanted to pair its PBM and 1,100 walk-in MinuteClinics with an insurer's 45 million members, giving it point-of-care access it lacked as a retailer alone.

Amazon's 2017 signal it might enter pharmacy, then its 2018 purchase of PillPack, made a defensive scale play more urgent for CVS.

Regulators had already blocked horizontal mergers (Aetna-Humana, Anthem-Cigna) in 2017, leaving a vertical PBM-insurer deal as the path open to combine at scale.

Vertical integration can outrun a single-channel threat, but it is bought with debt: Moody's cut CVS's credit rating the same day the deal closed.

The merger closed with the integration plan CVS called 'largely complete,' but Moody's downgraded CVS Health's senior unsecured rating the same day, citing the debt taken on to fund the deal alongside reimbursement pressure and integration risk. The material stops at the close; it does not cover how the $750 million cost-savings target or the clinic-insurance integration played out afterward.